Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Cancer Research UK’s Race for Life celebrates its 30th year by... April 24, 2023 Can Some People with Breast Cancer Safely Skip Lymph Node Radiation? January 23, 2024 Doctor Wipes Away The Debt Of 200 Cancer Patients January 6, 2021 EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel February 28, 2025 Load more HOT NEWS Blood test could tailor treatment after surgery Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer
